Total Payments
$34,071
2023 Payments
$7,180
Companies
8
Transactions
64
Payment Breakdown by Category
Consulting$18,430 (54.1%)
Research$10,740 (31.5%)
Travel$3,509 (10.3%)
Food & Beverage$1,384 (4.1%)
Education$7.48 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $18,430 | 6 | 54.1% |
| Unspecified | $10,740 | 19 | 31.5% |
| Travel and Lodging | $3,509 | 13 | 10.3% |
| Food and Beverage | $1,384 | 24 | 4.1% |
| Education | $7.48 | 2 | 0.0% |
Payments by Type
General
$23,331
45 transactions
Research
$10,740
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17,178 | 33 | $0 (2019) |
| PFIZER INC. | $7,510 | 4 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $5,908 | 9 | $0 (2018) |
| Regeneron Pharmaceuticals, Inc. | $2,976 | 14 | $0 (2020) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $254.67 | 1 | $0 (2018) |
| Seagen Inc. | $132.12 | 1 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $100.30 | 1 | $0 (2017) |
| Janssen Biotech, Inc. | $13.09 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $7,180 | 3 | PFIZER INC. ($7,180) |
| 2022 | $462.12 | 2 | PFIZER INC. ($330.00) |
| 2020 | $2,023 | 6 | Regeneron Pharmaceuticals, Inc. ($2,023) |
| 2019 | $1,815 | 9 | Regeneron Pharmaceuticals, Inc. ($952.81) |
| 2018 | $10,056 | 20 | Boehringer Ingelheim Pharmaceuticals, Inc. ($5,908) |
| 2017 | $12,535 | 24 | E.R. Squibb & Sons, L.L.C. ($12,435) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/31/2023 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 05/18/2023 | PFIZER INC. | — | — | In-kind items and services | $780.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 01/17/2023 | PFIZER INC. | IBRANCE (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 08/30/2022 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $132.12 | General |
| 02/15/2022 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 06/24/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $861.54 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/17/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $237.94 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/06/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $234.85 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/25/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $224.29 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/17/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $233.47 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/17/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $230.79 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/18/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $61.10 | Research |
| Study: Libtayo Clinical Publication Program • Category: ONCOLOGY | ||||||
| 11/15/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $61.10 | Research |
| Study: Libtayo Clinical Publication Program • Category: ONCOLOGY | ||||||
| 11/07/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $234.02 | Research |
| Study: Libtayo Clinical Publication Program • Category: ONCOLOGY | ||||||
| 10/29/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $247.57 | Research |
| Study: Libtayo Clinical Publication Program • Category: ONCOLOGY | ||||||
| 10/11/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $81.46 | Research |
| Study: Libtayo Clinical Publication Program • Category: ONCOLOGY | ||||||
| 09/05/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $137.96 | Research |
| Study: Libtayo Clinical Publication Program • Category: ONCOLOGY | ||||||
| 08/08/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $64.80 | Research |
| Study: Libtayo Clinical Publication Program • Category: ONCOLOGY | ||||||
| 08/07/2019 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $64.80 | Research |
| Study: Libtayo Clinical Publication Program • Category: ONCOLOGY | ||||||
| 03/15/2019 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $862.50 | General |
| 10/18/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,630.00 | General |
| 10/18/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 10/18/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 09/28/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Travel and Lodging | In-kind items and services | $684.24 | General |
| Category: ONCOLOGY | ||||||
| 09/28/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Travel and Lodging | In-kind items and services | $179.67 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,510 | 4 |
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $2,023 | 6 |
| Libtayo Clinical Publication Program | Regeneron Pharmaceuticals, Inc. | $952.81 | 8 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $254.67 | 1 |
About Dr. Nicholas Robert, M.D
Dr. Nicholas Robert, M.D is a Hematology & Oncology healthcare provider based in Fairfax, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992772925.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nicholas Robert, M.D has received a total of $34,071 in payments from pharmaceutical and medical device companies, with $7,180 received in 2023. These payments were reported across 64 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($18,430).
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Fairfax, VA
- Active Since 03/08/2006
- Last Updated 12/13/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1992772925
Products in Payments
- IBRANCE (Drug) $3,200
- LIBTAYO (Biological) $2,976
- GILOTRIF (Drug) $1,103
- OPDIVO (Biological) $575.00
- MEKINIST (Drug) $254.67
- Erleada (Drug) $13.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fairfax
Dr. William Ershler, M.d, M.D
Hematology & Oncology — Payments: $143,157
Hematology & Oncology $143,157
Nagla Abdel Karim, Md, MD
Hematology & Oncology — Payments: $126,207
Hematology & Oncology $126,207
Dipti Patel-Donnelly, M.d, M.D
Hematology & Oncology — Payments: $46,716
Hematology & Oncology $46,716
Daniel Chong, M.d, M.D
Hematology & Oncology — Payments: $19,434
Hematology & Oncology $19,434
Timothy Mccarthy, M.d, M.D
Hematology & Oncology — Payments: $7,653
Hematology & Oncology $7,653
Robert Reid, M.d, M.D
Hematology & Oncology — Payments: $3,049
Hematology & Oncology $3,049